AU2008258599B2 - Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission - Google Patents

Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission Download PDF

Info

Publication number
AU2008258599B2
AU2008258599B2 AU2008258599A AU2008258599A AU2008258599B2 AU 2008258599 B2 AU2008258599 B2 AU 2008258599B2 AU 2008258599 A AU2008258599 A AU 2008258599A AU 2008258599 A AU2008258599 A AU 2008258599A AU 2008258599 B2 AU2008258599 B2 AU 2008258599B2
Authority
AU
Australia
Prior art keywords
difluorophenyl
pyrrolidin
fluorophenyl
mmol
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2008258599A
Other languages
English (en)
Other versions
AU2008258599A1 (en
Inventor
Fredrik Pettersson
Clas Sonesson
Lars Swanson
Nicholas Waters
Susanna Waters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NSAB Filial af Neurosearch Sweden AB
Original Assignee
NSAB Filial af Neurosearch Sweden AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NSAB Filial af Neurosearch Sweden AB filed Critical NSAB Filial af Neurosearch Sweden AB
Publication of AU2008258599A1 publication Critical patent/AU2008258599A1/en
Assigned to NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE reassignment NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE Amend patent request/document other than specification (104) Assignors: NSAB, FILIAL OF NEUROSEARCH SWEDEN AB SVERIGE
Application granted granted Critical
Publication of AU2008258599B2 publication Critical patent/AU2008258599B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2008258599A 2007-06-05 2008-06-04 Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission Expired - Fee Related AU2008258599B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94199407P 2007-06-05 2007-06-05
US60/941,994 2007-06-05
SE0701387-3 2007-06-05
SE0701387 2007-06-05
PCT/EP2008/056915 WO2008148801A2 (en) 2007-06-05 2008-06-04 Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

Publications (2)

Publication Number Publication Date
AU2008258599A1 AU2008258599A1 (en) 2008-12-11
AU2008258599B2 true AU2008258599B2 (en) 2013-06-13

Family

ID=39743744

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008258599A Expired - Fee Related AU2008258599B2 (en) 2007-06-05 2008-06-04 Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

Country Status (16)

Country Link
US (1) US8188301B2 (OSRAM)
EP (1) EP2155671B8 (OSRAM)
JP (1) JP5444535B2 (OSRAM)
KR (1) KR20100038295A (OSRAM)
CN (1) CN101808987A (OSRAM)
AU (1) AU2008258599B2 (OSRAM)
BR (1) BRPI0812740A2 (OSRAM)
CA (1) CA2690091A1 (OSRAM)
CO (1) CO6251288A2 (OSRAM)
IL (1) IL202045A0 (OSRAM)
MX (1) MX2009012787A (OSRAM)
NZ (1) NZ581364A (OSRAM)
RU (1) RU2471781C2 (OSRAM)
UA (1) UA98783C2 (OSRAM)
WO (1) WO2008148801A2 (OSRAM)
ZA (1) ZA200908592B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100038295A (ko) 2007-06-05 2010-04-14 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 피질 카테콜아민성 신경 전달의 조정자로서의 이치환된 페닐피롤리딘
KR101660936B1 (ko) 2008-11-24 2016-10-05 인터그레이티브 리서치 래버러토리즈 스웨덴 에이비 피질 카테콜아민성 신경전달의 조절자로서의 ３-페닐-３-메톡시피롤리딘 유도체
WO2010058020A1 (en) * 2008-11-24 2010-05-27 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Novel 1 -alkyl- 3 -hydroxy- 3 -phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
CN102224135A (zh) 2008-11-24 2011-10-19 Nsab神经研究瑞典公司分公司 用作皮质儿茶酚胺能神经传递调节剂的新3-苯基-氮杂环丁烷衍生物
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
AR074755A1 (es) * 2008-12-16 2011-02-09 Astrazeneca Ab Derivados cuaternarios de piperidina y sus usos
IN2012DN00720A (OSRAM) 2009-07-06 2015-06-19 Ontorii Inc
WO2012039448A1 (ja) * 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
MX347361B (es) 2011-07-19 2017-04-12 Wave Life Sciences Ltd Metodos para la sintesis de acidos nucleicos funcionalizados.
AU2013287630B2 (en) 2012-07-13 2017-05-25 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
EP2872147B1 (en) 2012-07-13 2022-12-21 Wave Life Sciences Ltd. Method for making chiral oligonucleotides
EP2872485B1 (en) 2012-07-13 2020-12-16 Wave Life Sciences Ltd. Asymmetric auxiliary group
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
CN106068325B (zh) 2014-01-16 2021-07-09 波涛生命科学有限公司 手性设计
AU2016263510B2 (en) * 2015-05-20 2020-03-12 Integrative Research Laboratories Sweden Ab Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
ES2805031T3 (es) 2016-02-10 2021-02-10 Sumitomo Chemical Co Método de producción de 1-metilpirrolidin-3-ol
US11078158B2 (en) * 2017-05-19 2021-08-03 Integrative Research Laboratories Sweden Ab (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3118907A (en) * 1961-08-14 1964-01-21 Mead Johnson & Co 3-substituted-3-pyrrolidinols

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2878264A (en) * 1959-03-17 Substituted amino alcohols
DE1144279B (de) 1957-09-26 1963-02-28 Robins Co Inc A H Verfahren zur Herstellung von 3-Aryl-3-hydroxypyrrolidinen und deren Salzen
BE704683A (OSRAM) 1966-11-07 1968-02-15
US3647790A (en) * 1969-04-08 1972-03-07 American Home Prod Ouinoxalinyl-oxazolidines and -oxazines
US5128362A (en) * 1988-01-15 1992-07-07 Abbott Laboratories 1-aminomethyl-1,2,3,4-tetrahydronaphthalenes
DE3802175A1 (de) 1988-01-26 1989-08-03 Hoechst Ag N-phenylbenzamide und n-phenylbenzamidoxime, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als schaedlingsbekaempfungsmittel
DE3835291A1 (de) * 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
US5444083A (en) * 1989-02-03 1995-08-22 Eisai Co., Ltd. Pyrrolidine compound and pharmaceutical use
JP3176063B2 (ja) * 1991-04-17 2001-06-11 ファルマシア・アンド・アップジョン・カンパニー 新規中枢神経作用性置換フェニルアザシクロアルカン類
EP0586229A1 (en) * 1992-09-01 1994-03-09 Zeneca Limited 3-Hydroxy-3-(subst-akyl)-pyrrolidines as 5-lipoxygenase inhibitors
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
AU1208397A (en) 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
EP1098892A1 (en) 1998-07-20 2001-05-16 MERCK PATENT GmbH Biphenyl derivatives
US20020169155A1 (en) * 1998-09-04 2002-11-14 Millennium Pharmaceuticals, Inc. Chemokine receptor anagonists and methods of use therefor
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
DE19840611A1 (de) * 1998-09-05 2000-03-09 Klaus Wanner GABA-uptake-Inhibitoren mit Pyrrolidinstruktur
WO2000070531A2 (en) 1999-05-17 2000-11-23 The Foxboro Company Methods and apparatus for control configuration
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
ATE547404T1 (de) * 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
US7700587B2 (en) * 2004-09-07 2010-04-20 Florida A&M University Haloperidol analogs
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
US20090215742A1 (en) 2005-05-03 2009-08-27 Pfizer, Inc. Amide resorcinol compounds
WO2007053145A1 (en) 2005-11-04 2007-05-10 Florida A & M University Haloperidol analogs
RU2008129679A (ru) 2005-12-21 2010-01-27 Янссен Фармацевтика Н.В. (Be) Новые замещенные пиразиноновые производные для применения при мсн-1-опосредованных заболеваниях
KR20100038295A (ko) 2007-06-05 2010-04-14 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 피질 카테콜아민성 신경 전달의 조정자로서의 이치환된 페닐피롤리딘
CA2689692A1 (en) 2007-06-05 2008-12-11 Clas Sonesson New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3118907A (en) * 1961-08-14 1964-01-21 Mead Johnson & Co 3-substituted-3-pyrrolidinols

Also Published As

Publication number Publication date
US20100179211A1 (en) 2010-07-15
EP2155671B8 (en) 2018-02-21
JP2010529081A (ja) 2010-08-26
CO6251288A2 (es) 2011-02-21
MX2009012787A (es) 2009-12-15
WO2008148801A2 (en) 2008-12-11
ZA200908592B (en) 2011-02-23
WO2008148801A8 (en) 2009-12-10
AU2008258599A1 (en) 2008-12-11
KR20100038295A (ko) 2010-04-14
CA2690091A1 (en) 2008-12-11
JP5444535B2 (ja) 2014-03-19
BRPI0812740A2 (pt) 2016-07-19
CN101808987A (zh) 2010-08-18
EP2155671A2 (en) 2010-02-24
EP2155671B1 (en) 2017-12-20
RU2471781C2 (ru) 2013-01-10
RU2009143104A (ru) 2011-07-20
NZ581364A (en) 2011-10-28
US8188301B2 (en) 2012-05-29
WO2008148801A3 (en) 2009-01-29
IL202045A0 (en) 2010-06-16
UA98783C2 (en) 2012-06-25

Similar Documents

Publication Publication Date Title
AU2008258599B2 (en) Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
US9035073B2 (en) 3-phenyl-3-methoxy-pyrrolidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
EP2155669B1 (en) New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
EP1963268B1 (en) Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission
EP2367786B1 (en) Novel 1 -alkyl- 3 -hydroxy- 3 -phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
EP2367785B1 (en) Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
HK1147260A (en) Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application